Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'
Treasury Develolping Options to Curb Inversions (Fox Business)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
Jul 2014JP MorganReinstatesUnderweight
May 2014BarclaysMaintainsEqual-weight
May 2014DanskeDowngradesBuySell

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters